Scordo M, Wang TP, Ahn KW, et al. - Utilizing registry data from the Center for International Blood and Marrow Transplant Research registry, researchers conducted this observational cohort study to evaluate the outcomes in patients with primary central nervous system lymphoma (PCNSL) undergoing autologous hematopoietic cell transplant (AHCT) with the 3 most commonly used conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU), and carmustine/etoposide/cytarabine/melphalan (BEAM). Study participants received 1 of 3 conditioning regimens: TBC (n = 263), TT-BCNU (n = 275), and BEAM (n = 65). The sample consisted of 603 adult patients, the mean age was 57 (range, 19-77) years and 318 (53%) were male, with PCNSL undergoing AHCT. Age of 60 years or older, Karnofsky performance status less than 90, and an HCT-comorbidity index greater than or equal to 3 were linked to lower rates of survival across all 3 cohorts. Despite higher rates of early toxic effects and NRM in this cohort study, thiotepa-based conditioning regimen was associated with higher rates of survival compared to BEAM; these findings may help clinicians choose between TBC and TT-BCNU based on patient and disease characteristics.